The HSP90 inhibitor, 17AAG, protects the intestinal stem cell niche and inhibits graft versus host disease development.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

7 citing papers in PubMed.

1. Organoids as a tool to study homeostatic and pathological immune-epithelial interactions in the gut.Clinical and experimental immunology · 2024
   Review
2. CD11c participates in triggering acute graft-versus-host disease during bone marrow transplantation.Immunology · 2021
   Article
3. Selecting the first chemical molecule inhibitor of HSP110 for colorectal cancer therapy.Cell death and differentiation · 2020
   Article
4. Immunophenotypic and molecular comparison between allogeneic and autologous graft-vs-host disease of the skin: A retrospective study using immunohistochemical and proteomics methods.Journal of cutaneous pathology · 2017
   Article
5. Hsp90 inhibition destabilizes Ezh2 protein in alloreactive T cells and reduces graft-versus-host disease in mice.Blood · 2017
   Article
6. Secreted heat shock protein 90 promotes prostate cancer stem cell heterogeneity.Oncotarget · 2017
   Article
7. New insights into the unfolded protein response in stem cells.Oncotarget · 2016
   Review

Corrections and comments

• Erratum for
  The HSP90 inhibitor, 17AAG, protects the intestinal stem cell niche and inhibits graft versus host disease development.2016

Authors and funding

17 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.